{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-002602","form_type":"8-K/A","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.317167+00:00","generated_at":"2026-05-23T22:26:34.499643+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bioxytran acquires NDPD Pharma in $15.85M stock deal; CFO adopts 10b5-1 plan","bullets":["Acquired 100% of NDPD Pharma for 3,389,169 common shares and 28,467,564 preferred shares valued at ~$12.46M.","NDPD held patents for PLM (PHGG) to treat COVID-19 and 60+ viruses; appraised asset value $15.85M including license.","Related-party accounting (ASC 805-50) requires purchase price of $12.47M to be eliminated against equity, not recorded as assets.","CFO Ola Soderquist adopted a 10b5-1 plan to sell up to 500,000 shares by Dec 31, 2025, contingent on price thresholds.","NDPD was beneficially owned by company officers; transaction approved by board as a related-party acquisition."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-002602","json":"https://secwatch.observer/filing/0001641172-25-002602.json","markdown":"https://secwatch.observer/filing/0001641172-25-002602.md","text":"https://secwatch.observer/filing/0001641172-25-002602.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000164117225002602/0001641172-25-002602-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000164117225002602/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T22:26:34.499643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}